LEO Pharma A/S
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From LEO Pharma A/S
When it comes to building innovative pipelines and raising cash, Scandinavia is giving the rest of Europe a run for its money.
Astellas makes targeted acquisition of small, private US venture in apparent move to shore up its prostate cancer franchise amid a looming major patent expiry.
Lilly looks To Elektrofi for help on subcutaneous injectable therapies, while NAYA will merge with INVO and acquire two antibodies from Cytovia. Plus deals involving Hummingbird/Endeavor, Basilea/Gravitas/Intron, Lilly/Mablink and Sotio/Synaffix.
In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb highlights interviews with behavioral health experts on implementing AI solutions to help ease the administrative burden on clinicians as well as recent coverage from the LSX Congress USA and HLTH conferences. Reed Miller discusses findings of EY’s annual pulse of the medtech industry report and Hannah Daniel discusses FDA guidance on regulating AI/ML.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- LEO Pharma Inc.
- Peplin, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.